基于原发疾病与治疗方式解析治疗相关骨髓增生异常综合征:一项全国性研究
这项基于瑞典全国MDS登记库的人群研究纳入2009至2017年诊断的2705例MDS患者,比较治疗相关MDS(t-MDS)亚组并分析既往治疗类型与原发疾病的影响。t-MDS中位生存短于原发MDS(15.8个月 vs 31.1个月,p < 0.001);仅放疗者疾病特征与de novo MDS高度相似,化疗者风险显著更高。
要点
- t-MDS中位生存15.8个月,短于原发MDS的31.1个月(p < 0.001)。
- 仅放疗的t-MDS疾病特征与de novo MDS高度相似。
- 化疗后的t-MDS风险特征显著更高。
核心结论
- 全国性t-MDS研究证实t-MDS中位生存短于de novo MDS(15.8个月 vs 31.1个月,p < 0.001)。
- 仅放疗的t-MDS疾病特征与de novo MDS高度相似,化疗后t-MDS风险特征显著更高。
- 既往血液系统恶性肿瘤的t-MDS患者预后差,源于原发疾病相关死亡和高危MDS。
研究设计与样本
- 基于人群的研究,合并瑞典全国MDS登记库2009至2017年诊断的2705例MDS患者与多个健康登记库数据。
- 使用匹配的人群对照,比较MDS患者与一般人群既往恶性肿瘤的患病率。
主要发现
- t-MDS中位生存15.8个月 vs de novo MDS 31.1个月(p < 0.001)。
- 仅放疗的t-MDS疾病特征与de novo MDS高度相似,化疗后t-MDS风险特征显著更高。
- IPSS-R和WHO分类可将t-MDS分为不同风险组。
- 与对照相比,MDS患者既往血液系统恶性肿瘤患病率增加六倍,既往实体瘤患病率仅增加34%。
- 既往血液系统恶性肿瘤的t-MDS患者预后差,源于原发疾病相关死亡和高危MDS。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this population-based study, we aimed to characterize and compare subgroups of therapy-related Myelodysplastic syndromes (t-MDS) and define the implications of type of previous treatment and primary disease. We combined data from MDS patients, diagnosed between 2009 and 2017 (n = 2705), in the nationwide Swedish MDS register, with several health registers. Furthermore, using matched population controls, we investigated the prevalence of antecedent malignancies in MDS patients in comparison with the general population. This first ever nationwide study on t-MDS confirms a shorter median survival for t-MDS compared to de novo MDS (15.8 months vs 31.1 months, p < 0.001). T-MDS patients previously treated with radiation only had disease characteristics with a striking resemblance to de novo-MDS, in sharp contrast to patients treated with chemotherapy who had a significantly higher risk profile. IPSS-R and the WHO classification differentiated t-MDS into different risk groups. As compared with controls, MDS patients had a six-fold increased prevalence of a previous hematological malignancy but only a 34% increased prevalence of a previous solid tumor. T-MDS patients with a previous hematological malignancy had a dismal prognosis, due both to mortality related to their primary disease and to high-risk MDS.
引用
- Moreno Berggren D, Garelius H, Willner Hjelm P, et al. Therapy-related MDS dissected based on primary disease and treatment-a nationwide perspective. Leukemia. 2023. PMID: 36928008. doi:10.1038/s41375-023-01864-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。